Home › Companies › Syros Pharmaceuticals Inc.

Syros Pharmaceuticals Inc. proxy voting records

How asset managers voted at Syros Pharmaceuticals Inc.’s shareholder meetings, one page per proxy season, compiled from the votes funds and managers report on SEC Form N-PX and the company’s own results on Form 8-K.

CUSIP issuer number87184Q
SEC CIK1556263

Recent shareholder votes

June 5, 2024 annual meeting (2023-2024 proxy season): 8 items in Syros Pharmaceuticals Inc.'s official results (Form 8-K, filed June 6, 2024); lowest support 57% of votes cast (Elect Director: Srinivas Akkaraju, M.D., Ph.D.). Full results and how funds voted.

Each line is the company’s own Form 8-K tally as shown on that season’s page; support is FOR as a share of votes cast.

Proxy seasons

Season	Filed as	Ballot items	Asset managers
2023-2024	SYROS PHARMACEUTICALS INC.	8	67

Earlier seasons list this company under the name SYROS PHARMACEUTICALS INC., as its holders filed it.

Explore Syros Pharmaceuticals Inc. in the interactive database

The seasons are grouped by the issuer number in the company’s CUSIP, not by its name. This page is rebuilt weekly; built November 9, 2026.